

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 9989)**

**DATE F B A D \_ E E T \_ G**

The board of directors (the “**B\_ \_ \_**”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**C\_ \_ \_**”), and together with its subsidiaries, the “**G\_ \_ \_**”) hereby announces that a meeting of the Board will be held on Thursday, March 28, 2024 for the purposes of, among other matters, approving the annual results of the Group for the year ended December 31, 2023 and its publication, and considering the recommendation of a final dividend, if any.

By Order of the Board

  **G\_ \_ \_ C\_ \_ \_**

*Chairman*

Shenzhen, PRC  
March 15, 2024

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.*